button bars forest bayes pooled summary circles
 
deaths (OS)progression or deaths (PFS)RFS/DFS

mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - all population

versus placebo plus SoC
sintillimab plus SoC vs. placebo plus SoC 1 certainty unassessable-36% certainty unassessablestatistically conclusive-48%-
versus Standard of Care (SoC)
cemiplimab vs. Standard of Care (SoC) 1 certainty unassessablestatistically conclusive-29% certainty unassessablestatistically conclusive-38%-
durvalumab alone vs. Standard of Care (SoC) 1 certainty unassessable-4%--

mNSCLC - L1 - PDL1 negative metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 negative

versus pemetrexed plus platin
nivolumab plus SoC vs. pemetrexed plus platin 1 certainty unassessable-20% certainty unassessablestatistically conclusive-25%-

mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive

versus Standard of Care (SoC)
atezolizumab alone vs. Standard of Care (SoC) 3 certainty unassessable-16% certainty unassessable-21%-
cemiplimab vs. Standard of Care (SoC) 1 certainty unassessable-40% certainty unassessable-42%-
durvalumab alone vs. Standard of Care (SoC) 1 certainty unassessable-22% certainty unassessable-12%-
nivolumab alone vs. Standard of Care (SoC) 2 certainty unassessable+7% certainty unassessable+17%-
pembrolizumab alone vs. Standard of Care (SoC) 4 statistically conclusive-24%-24%-

mNSCLC - L1 - TMB>10Mb metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - TMB10Mb

non squamous - mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - all population

versus atezolizumab plus carboplatin plus nab-paclitaxel
atezolizumab plus carboplatin plus nab-paclitaxel vs. atezolizumab plus carboplatin plus nab-paclitaxel 1 certainty unassessablestatistically conclusive-18% certainty unassessablestatistically conclusive-32%-
versus bevacizumab plus carboplatin and paclitaxel
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel 1 certainty unassessable-22% certainty unassessable-36%-
atezolizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel 1 certainty unassessable-14% certainty unassessable-8%-

non squamous - mNSCLC - L1 - Wild Type (WT) metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - Wild Type (WT)

versus bevacizumab plus carboplatin and paclitaxel
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel 2 certainty unassessablestatistically conclusive-20%statistically conclusive-38%-
versus carboplatin plus nab-paclitaxel
atezolizumab plus carboplatin plus nab-paclitaxel vs. carboplatin plus nab-paclitaxel 1 certainty unassessablestatistically conclusive-19% certainty unassessablestatistically conclusive-33%-
versus pemetrexed plus platin
atezolizumab plus pemetrexed and platin vs. pemetrexed plus platin 1 certainty unassessable-17% certainty unassessablestatistically conclusive-37%-
pembrolizumab and pemetrexed plus platin vs. pemetrexed plus platin 1 certainty unassessable-9% certainty unassessablestatistically conclusive-43%-
versus placebo plus SoC
pembrolizumab plus SoC vs. placebo plus SoC 1 certainty unassessablestatistically conclusive-47% certainty unassessablestatistically conclusive-44%-

squamous - mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) squamous cell - mNSCLC - L1 squamous - mNSCLC - L1 - all population

versus carboplatin plus nab-paclitaxel
atezolizumab plus carboplatin plus nab-paclitaxel vs. carboplatin plus nab-paclitaxel 1 certainty unassessable-11% certainty unassessablestatistically conclusive-27%-
versus placebo plus SoC
pembrolizumab plus SoC vs. placebo plus SoC 1 certainty unassessablestatistically conclusive-33% certainty unassessablestatistically conclusive-40%-

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons